Bone Biologics filed a USPTO patent for NELL-1 and announced a $5 million offering to support trials and expand its bone regeneration patent portfolio.
Bone Biologics filed a USPTO patent for NELL-1 and announced a $5 million offering to support trials and expand its bone regeneration patent portfolio.